Peter Johnson

40.2k total citations · 7 hit papers
612 papers, 23.8k citations indexed

About

Peter Johnson is a scholar working on Pathology and Forensic Medicine, Immunology and Oncology. According to data from OpenAlex, Peter Johnson has authored 612 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 202 papers in Pathology and Forensic Medicine, 171 papers in Immunology and 150 papers in Oncology. Recurrent topics in Peter Johnson's work include Lymphoma Diagnosis and Treatment (195 papers), Chronic Lymphocytic Leukemia Research (84 papers) and Monoclonal and Polyclonal Antibodies Research (78 papers). Peter Johnson is often cited by papers focused on Lymphoma Diagnosis and Treatment (195 papers), Chronic Lymphocytic Leukemia Research (84 papers) and Monoclonal and Polyclonal Antibodies Research (78 papers). Peter Johnson collaborates with scholars based in United Kingdom, United States and Italy. Peter Johnson's co-authors include Martin J. Glennie, Judith N. Bulmer, W. Pagé Faulk, John Radford, Graham Packham, Keith W. Caldecott, Mark S. Cragg, Ruth R. French, Saïd Aoufouchi and Andrew Jack and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Peter Johnson

593 papers receiving 23.0k citations

Hit Papers

Rituximab (anti-CD20 monoclonal antibody) for the treatme... 1996 2026 2006 2016 1998 2015 1996 2015 2013 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
    1998 724 citations Peter Johnson, John Radford et al. Blood profile →
  2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2015 611 citations Umberto Vitolo, Andrew Jack et al. profile →
  3. XRCC1 Polypeptide Interacts with DNA Polymerase   and Possibly Poly (ADP-Ribose) Polymerase, and DNA Ligase III Is a Novel Molecular 'Nick-Sensor' In Vitro
    1996 529 citations Peter Johnson et al. profile →
  4. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
    2015 407 citations John Radford, Tim Illidge et al. profile →
  5. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
    2013 357 citations David Cunningham, Andrew Jack et al. The Lancet profile →
  6. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
    2021 212 citations Martin Hutchings, Rogier Mous et al. The Lancet profile →
  7. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study
    2021 196 citations Peter Johnson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Johnson United Kingdom 78 7.8k 7.5k 7.0k 5.5k 3.8k 612 23.8k
John P. Leonard United States 67 9.4k 1.2× 6.7k 0.9× 3.1k 0.4× 4.2k 0.8× 3.1k 0.8× 490 17.1k
Andreas Engert Germany 72 12.1k 1.6× 9.2k 1.2× 4.1k 0.6× 2.2k 0.4× 2.8k 0.7× 552 20.7k
Bernd Dörken Germany 81 4.8k 0.6× 8.6k 1.2× 5.0k 0.7× 8.6k 1.6× 1.1k 0.3× 412 22.0k
Volker Diehl Germany 82 17.4k 2.2× 14.0k 1.9× 6.2k 0.9× 3.8k 0.7× 3.9k 1.0× 696 31.2k
Leo I. Gordon United States 65 8.0k 1.0× 6.6k 0.9× 2.2k 0.3× 2.3k 0.4× 3.1k 0.8× 453 15.0k
Steven T. Rosen United States 61 6.5k 0.8× 5.7k 0.8× 3.3k 0.5× 4.5k 0.8× 1.3k 0.4× 423 15.9k
Ranjana H. Advani United States 66 13.5k 1.7× 10.2k 1.4× 4.6k 0.7× 2.4k 0.4× 1.5k 0.4× 456 20.0k
Lee M. Nadler United States 79 3.9k 0.5× 6.5k 0.9× 14.5k 2.1× 5.1k 0.9× 4.0k 1.1× 268 24.6k
Richard I. Fisher United States 73 18.9k 2.4× 16.2k 2.2× 5.9k 0.8× 4.0k 0.7× 3.6k 1.0× 333 31.5k
Jamés O. Armitage United States 74 15.9k 2.0× 12.4k 1.7× 4.0k 0.6× 2.5k 0.5× 1.8k 0.5× 487 25.6k

Countries citing papers authored by Peter Johnson

Since Specialization
Citations

This map shows the geographic impact of Peter Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Johnson more than expected).

Fields of papers citing papers by Peter Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Johnson. The network helps show where Peter Johnson may publish in the future.

Co-authorship network of co-authors of Peter Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Johnson. A scholar is included among the top collaborators of Peter Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Johnson. Peter Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ceriani, Luca, Lisa Milan, Maria Cristina Pirosa, et al.. (2025). PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient Cohort. Journal of Nuclear Medicine. 66(2). 209–214. 2 indexed citations
2.
Luminari, Stefano, Alexander Fosså, Judith Trotman, et al.. (2023). Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. Journal of Clinical Oncology. 42(1). 13–18. 16 indexed citations
3.
Mak, Jonathan K. L., Sara Hägg, Maria Eriksdotter, et al.. (2022). Development of an Electronic Frailty Index for Hospitalized Older Adults in Sweden. The Journals of Gerontology Series A. 77(11). 2311–2319. 21 indexed citations
4.
Nicholas, Ben, A.G. Bailey, Katy J. McCann, et al.. (2022). Identification of neoantigens in oesophageal adenocarcinoma. Immunology. 168(3). 420–431. 6 indexed citations
5.
Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet. 398(10306). 1157–1169. 212 indexed citations breakdown →
6.
Xu, Hong, Sara García‐Ptacek, Martin Annetorp, et al.. (2021). Acute kidney injury and mortality risk in older adults with COVID-19. Journal of Nephrology. 34(2). 295–304. 19 indexed citations
7.
Chiodin, Giorgia, Annalisa D’Avola, Ian Tracy, et al.. (2018). Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. Clinical Cancer Research. 25(8). 2503–2512. 19 indexed citations
8.
Blunt, Matthew D., Stefan Koehrer, Rachel Dobson, et al.. (2016). The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(9). 2313–2324. 54 indexed citations
9.
10.
Williams, Emily L., Sonya James, Peter Johnson, et al.. (2013). Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model. Clinical Cancer Research. 19(13). 3545–3555. 34 indexed citations
11.
12.
13.
Zucca, Emanuele, Annarita Conconi, Daniele Laszlò, et al.. (2013). Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. Journal of Clinical Oncology. 31(5). 565–572. 148 indexed citations
14.
King, Ben C., Angela Hamblin, Philip Savage, et al.. (2013). Antibody–peptide–MHC fusion conjugates target non-cognate T cells to kill tumour cells. Cancer Immunology Immunotherapy. 62(6). 1093–1105. 9 indexed citations
15.
Beers, Stephen A., Ruth R. French, H.T. Claude Chan, et al.. (2010). Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 115(25). 5191–5201. 241 indexed citations
16.
Hoskin, Peter, Lisa Lowry, Alan Horwich, et al.. (2009). Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology. 27(32). 5390–5396. 124 indexed citations
17.
Du, Yong, Jamie Honeychurch, Martin J. Glennie, Peter Johnson, & Tim Illidge. (2007). Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma. Cancer Research. 67(3). 1335–1343. 8 indexed citations
18.
Michels, Jorg, Peter Johnson, & Graham Packham. (2004). Mcl-1. The International Journal of Biochemistry & Cell Biology. 37(2). 267–271. 184 indexed citations
19.
Johnson, Peter, et al.. (2001). A SIGNIFICANT RANGE EXTENSION OF THE PURPLE-NECKED ROCK- WALLABY PETROGALE PURPUREICOLLIS. Australian Mammalogy. 200(2-3). 71–73. 4 indexed citations
20.
Risk, Janet M. & Peter Johnson. (1990). Northern blot analysis of HLA-G expression by BeWo human choriocarcinoma cells. Journal of Reproductive Immunology. 18(2). 199–203. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John P. Leonard Breakdown of academic impact, for papers by Andreas Engert Breakdown of academic impact, for papers by Bernd Dörken Breakdown of academic impact, for papers by Volker Diehl Breakdown of academic impact, for papers by Leo I. Gordon Breakdown of academic impact, for papers by Steven T. Rosen Breakdown of academic impact, for papers by Ranjana H. Advani Breakdown of academic impact, for papers by Lee M. Nadler Breakdown of academic impact, for papers by Richard I. Fisher Breakdown of academic impact, for papers by Jamés O. Armitage
Rankless by CCL
2026